Sojournix to Present at Evercore ISI 3rd Annual HealthCONx Virtual Conference

Tags:  

WALTHAM, Mass.--(BUSINESS WIRE)--Sojournix, a clinical-stage biopharmaceutical company dedicated to developing and commercializing transformative new medicines for the treatment of women’s health and neuroendocrine disorders, announces that Daniel Grau, Chief Executive Officer of Sojournix, will participate in a fireside chat discussing company progress at the Evercore ISI 3rd Annual HealthCONx Virtual Conference on Thursday, December 3 at 3:05pm ET.

About Sojournix

Sojournix is a clinical-stage biopharmaceutical company dedicated to developing and commercializing transformative new medicines for the treatment of women’s health and neuroendocrine disorders. The company is developing SJX-653, a novel, potent, selective neurokinin 3 (NK3) antagonist as a non-hormonal once-daily therapy for moderate to severe vasomotor symptoms (commonly called hot flashes) due to menopause. NK3 antagonism is a clinically and genetically validated new approach to treating menopausal hot flashes that targets the excessive signaling of neurokinin B through NK3 receptors in the hypothalamic area of the brain that regulates heat dissipation. To learn more about Sojournix, please visit www.sojournixpharma.com.

---

---

Contacts

Kathryn Morris kathryn@theyatesnetwork.com 914-204-6412

Kathryn Morris kathryn@theyatesnetwork.com 914-204-6412